Home / Congress Presentations / C3G and Primary IC-MPGN / National Kidney Foundation Spring Clinical Meetings (NKF SCM) 2025
Landing
National Kidney Foundation Spring Clinical Meetings (NKF SCM) 2025
Pegcetacoplan for adolescents with C3G or IC-MPGN in phase 3 VALIANT
Pegcetacoplan for posttransplant recurrent C3 glomerulopathy or primary (idiopathic) immune complex-mediated glomerulonephritis: The VALIANT trial
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.